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ABSTRACT
This article explores Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Laboratories, Inc., 933
F.3d 1367, 1375 (Fed. Cir. 2019), and focuses on the issue of nonobviousness under 35
U.S.C. § 103. The Federal Circuit has developed the lead compound analysis for
determining whether a pharmaceutical compound is obvious in view of a lead
compound and other prior art references. The key question is whether an ordinary
skilled chemist would have a motivation or reason to select a lead compound and
modify it to arrive at the claim compound. The Sanofi-Aventis court further provided
an evidentiary rule that the motivation or reason should be based on both the
structural similarity of tested prior art compounds and the test results of these
compounds. This article argues that the Sanofi-Aventis approach not only follows the
Supreme Court’s principles, but also is beneficial to ongoing drug development.
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I. INTRODUCTION
Paclitaxel, docetaxel, and cabazitaxel (shown in Figures 1(a), 2(a) & 2(b)) are
three cancer drugs (antimicrotubule chemotherapy agents) of the taxane family.1 In
the 1960s, a research project funded by the National Cancer Institute (“NCI”) first
isolated paclitaxel (Taxol®) as a natural compound from the bark of the Pacific yew
tree (Taxus brevifolia). 2 In the late 1970s, paclitaxel was identified as showing
antitumor activity in the mouse melanoma B16 model.3 However, it was not until
1994 that Bristol-Myers Squibb (“BMS”) completed a semisynthetic process for
manufacturing paclitaxel without killing endangered Pacific yew trees. 4 BMS’
process utilized a precursor, 10-deacetyl-baccatin III (10-DAB shown in Figure 1(b))
extracted from the common yew tree (Taxus baccata).5 Finally, the U.S. Food and
Drug Administration (“FDA”) approved Taxol® for treating ovarian cancer in 1992
and breast cancer in 1994.6
*
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article are derived from relevant Wikipedia information and court decisions under the fair-use
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1 Boyang Sun, Robert M. Straubinger & Jonathan F. Lovell, Current Taxane Formulations and
Emerging Cabazitaxel Delivery Systems, 11(10) NANO RESEARCH 5193, 5193 (2018); see also
National Cancer Institute, NCI Dictionary of Cancer Terms-Antimicrotubule Agent, NCI.GOV,
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antimicrotubule-agent
(last
visited Jan. 17, 2020) (A “antimicrotubule agent” is a “type of drug that blocks cell growth by
stopping mitosis (cell division) [through interfering] with microtubules (cellular structures that help
move chromosomes during mitosis).”).
2
NATIONAL
CANCER
INSTITUTE,
SUCCESS
STORY:
TAXOL®
(NSC
125973),
https://dtp.cancer.gov/timeline/flash/success_stories/S2_Taxol.htm (last visited Jan. 16, 2020)
[hereinafter NATIONAL CANCER INSTITUTE, TAXOL®]; see Matthieu Picard & Mariana C. Castells,
Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review, 49(2) CLINICAL
REVIEWS IN ALLERGY & IMMUNOLOGY 177, 178 (2015).
3 George Frisvold & Kelly Day-Rubenstein, Bioprospecting and Biodiversity Conservation: What
Happens When Discoveries Are Made?, 50 ARIZ. L. REV. 545, 558-59 (2008) (describing the discovery
and development of Taxol®); see NATIONAL CANCER INSTITUTE, TAXOL®, supra note 2; see Beth A.
Weaver, How Taxol/Paclitaxel Kills Cancer Cells, 25 MOLECULAR BIOLOGY OF THE CELL 2677, 267778 (2014).
4 Picard & Castells, supra note 2, at 178.
5 Id.
6 Weaver, supra note 3, at 2678 (Table 1).
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(a) Paclitaxel

Figure 1

(b) 10-Deacetylbaccatin III

Docetaxel (Taxotère®) was developed as a substitute to paclitaxel by RhonePoulenc Rorer (“RPR”) and Centre National de la Recherche Scientifique, France
during the late 1980s and early 1990s. 7 Docetaxel was also semisynthesized by
utilizing 10-DAB as a precursor.8 Since the FDA approved Taxotère® for treating
advanced breast cancer in 1996,9 docetaxel has been proved to improve the survival
rate of patients with metastatic breast cancer better than paclitaxel.10
Docetaxel and paclitaxel are structurally similar except that the benzamide
functional group (Ph(C=O)NH- at C’3) and acetoxy (CH3C(=O)-O- at C10) in
paclitaxel (shown in Figure 1(a)) are replaced by the tert-butyl carbamate functional
group (t-BuO(C=O)NH- at C’3) and hydroxyl group (HO- at C10) in docetaxel (shown
in Figure 2(a)). 11 However, they are different in their molecular pharmacology,
pharmacokinetics, and pharmacodynamic profiles.12
Cabazitaxel (Jevtana®, shown in Figure 2(b)) is the second generation of
taxanes for treating cancer.13 Around 1989, Sanofi-Aventis began to search for taxane
7 Eric K. Rowinsky, The Development and Clinical Utility of the Taxane Class of
Antimicrotubule Chemotherapy Agents, 48 ANN. REV. OF MED. 353, 354 (1997); see N Katsumata,
Docetaxel: An Alternative Taxane in Ovarian Cancer, 89 (Suppl. 3) BRITISH J. OF CANCER S9, S9-S10
(2003); see also Aventis Pharma S.A. v. Hospira, Inc., 743 F. Supp. 2d 305, 320 (D. Del. 2010)
(describing the clinic test of Taxotere®); I Adachi, A Late Phase II Study of RP56976 (Docetaxel) in
Patients with Advanced or Recurrent Breast Cancer, 73 BRITISH J. OF CANCER 210, 210 (1996).
8 Rowinsky, supra note 7, at 354.
9 Iwao Ojima, Scott D. Kuduk & Subrata Chakravarty, Recent Advances in the Medicinal
Chemistry of Taxoid Anticancer Agents, 4 ADVANCES IN MED. CHEMISTRY 69, 71 (1999).
10 T. Vu et al., Survival Outcome and Cost-Effectiveness with Docetaxel and Paclitaxel in
Patients with Metastatic Breast Cancer: A Population-Based Evaluation, 19(3) ANNALS OF
ONCOLOGY 461, 463-64 (2008).
11 Ojima et al., supra note 9, at 71.
12 Iain Brown, Jay N. Sangrithi-Wallace & Andrew C. Schofield, Antimicrotubule Agents,
ANTICANCER THERAPEUTICS 79, 81 (2008).
13 Sun et al., supra note 1, at 5193.
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analogs to treat cancers.14 Taking docetaxel and paclitaxel as reference compounds,
Sanofi-Aventis ended up with finding cabazitaxel in 1994. 15 Cabazitaxel is
structurally similar to docetaxel, but two methoxy (H3CO-) groups of cabazitaxel
substitute for hydroxyl groups at C7 and C10 positions of docetaxel, as shown in
Figure 2.16
Cabazitaxel was selected after a preclinical screening process aiming at finding
“a compound as potent as docetaxel in tumor models sensitive to docetaxel and more
potent than docetaxel in tumors resistant to chemotherapy[.]”17 The drug resistance
to taxanes in tumor cells is mainly associated with increased expression of multidrug
resistance (“MDR1”) gene that encodes P-glycoprotein (“Pgp”).18 Pgp is a drug efflux
pump that removes drug molecules from a tumor cell. 19 Pgp decreases the
intracellular concentration of anticancer drugs in a tumor cell, which inhibits the
therapeutic effect.20
On June 17, 2010, the FDA approved Jevtana® for a treatment in combination
with prednisone for men with metastatic castration-resistant prostate cancer
(“mCRPC”) who had already received a docetaxel-containing regimen. 21 The
“Approved Drug Products with Therapeutic Equivalence Evaluations” (a.k.a “Orange
Book”) lists three patents for Jevtana®: U.S. Patent Nos. 5,847,170 (’170 Patent),
7,241,907, and 8,927,592 (’592 Patent).22

14 Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG, 2018 WL
9364037, at *4-*5 (D.N.J. Apr. 25, 2018).
15 Id. at *4.
16 Olga Azarenko et al., Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel
as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells, 13(8) MOLECULAR
CANCER THERAPEUTICS 2092, 2093 (2014).
17 Hervé Bouchard et al., Novel Taxanes: Cabazitaxel Case Study, ANALOGUE-BASED DRUG
DISCOVERY III 319, 324 (2013).
18 Eugene Mechetner et al., Levels of Multidrug Resistance (MDR1) P-glycoprotein Expression by
Human Breast Cancer Correlate with In Vitro Resistance to Taxol and Doxorubicin, 4 CLINICAL
CANCER RESEARCH 389, 389 (1998); see also Afroz Abidi, Cabazitaxel: A Novel Taxane for Metastatic
Castration-Resistant Prostate Cancer-Current Implications and Future Prospects, 4(4) J. OF
PHARMACOLOGY AND PHARMACOTHERAPEUTICS 230, 232 (2013).
19 Abidi, supra note 18, at 232.
20 Ziyad Binkhathlan & Afsaneh Lavasanifar, P-glycoprotein Inhibition as a Therapeutic
Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives,
13(3) CURRENT CANCER DRUG TARGETS 326, 329 (2013).
21 Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG, 2018 WL
9364037, at *3 (D.N.J. Apr. 25, 2018); see Ginah Nightingal & Jae Ryu, Cabazitaxel (Jevtana)-A
Novel Agent for Metastatic Castration-Resistant Prostate Cancer, 37(8) PHARMACY AND
THERAPEUTICS 440, 441 (2012).
22 U.S. FOOD AND DRUG ADMINISTRATION [FDA], PATENT AND EXCLUSIVITY FOR: N201023,
https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=201023
&Appl_type=N (last visited Mar. 2, 2020).
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(a) Docetaxel

(b) Cabazitaxel
Figure 2
The ’170 Patent is entitled “Taxoids, Their Preparation and Pharmaceutical
Compositions Containing Them.”23 Claim 1 recites “4α-Acetoxy-2α-benzoyloxy-5β,20epoxy-1β-hydroxy-7β,10β-dimethoxy-9-oxo-11-taxen-13α-yl(2R,3S)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate,” 24 which is the chemical
formula of cabazitaxel.25 Claim 2 recites “[a] pharmaceutical composition comprising
at least the product according to claim 1 in combination with one or more
See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *2.
Taxoids, Their Preparation and Pharmaceutical Compositions Containing Them, U.S. Patent
No. 5,847,170 claim 1 (filed Mar. 26, 1996) (issued Dec. 8, 1998).
25 See Crystalline Form of Cabazitaxel and Process for Preparing the Same, U.S. Patent No.
9,309,210 abstract (issued Apr. 12, 2016).
23
24
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pharmaceutically acceptable diluents or adjuvants and optionally one or more
compatible and pharmacologically active compounds.”26
From 2014 to 2016, several generic drug companies filed an abbreviated new
drug application (“ANDA”) for Jevtana®. 27 The ’170 Patent and ’592 Patent were
alleged to be invalid, which triggered multiple patent lawsuits brought by SanofiAventis against these generic drug companies.28 The lawsuits were consolidated in
the United States District Court for the District of New Jersey.29
The defendants contended that claims 1 and 2 of the ’170 Patent violated 35
U.S.C. § 103.30 Section 103 requires that an invention may not be patented if the
differences between the claimed invention and prior art are such that the claimed
invention as a whole would have been obvious to a person having ordinary skill in the
art before a specific date required by the patent law. 31 The key issue here was
“whether a skilled artisan would have been motivated to replace the C7 and C10
hydroxyl groups of docetaxel with the methoxy groups of cabazitaxel.”32 Eventually,
the district court found the disputed claims non-obvious in light of seven expert
witnesses and seventeen prior art references.33
In 2019, the Federal Circuit in Sanofi-Aventis U.S., LLC v. Dr. Reddy’s
Laboratories, Inc. upheld the district court’s nonobviousness decision.34 This article
attempts to demonstrate that the Sanofi-Aventis approach is an appropriate
standard for the nonobviousness requirement of pharmaceutical compound patents,
because the Sanofi-Aventis approach makes more likely patentable a pharmaceutical
compound developed in the context of ongoing efforts among competing research
groups.

‘170 Patent, claim 2.
See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *3. The ANDA process can speed
marketing of a generic version of a previously-approved new drug or pioneer drug without going
through a full-scale clinic trial to show safety and effectiveness as the new drug had. See David C.
McPhie, Old Drugs, New Uses: Solving A Hatch-Waxman Patent Predicament, 59 FOOD & DRUG L.J.
155, 158-59 (2004) (describing ANDA). Instead, showing that a generic version is bioequivalent to its
pioneer counterpart is enough. The ANDA process requires a generic drug company to submit a
Paragraph IV certificate if it wants the approval of its generic drug to be granted before the patents
listed in the Orange Book for the pioneer drug expire. The process of filing a Paragraph IV
certificate involves a patent dispute resolution mechanism. A generic drug company is obligated to
challenge the validity of the relevant patents or assert non-infringement of these patents. To stop a
generic version being marketed, a pioneer drug company has to sue the generic drug company for
patent infringement under 35 U.S.C. § 271(e). See Quincy (Ping-Hsun) Chen, Destroying A
Pharmaceutical Patent for Saving Lives?: A Case Study of Sanofi-Synthelabo v. Apotex, Inc., 21 ALB.
L.J. SCI. & TECH. 125, 133 (2011).
28 Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG, 2018 WL
9364037, at *1-*3 (D.N.J. Apr. 25, 2018).
29 Id.
30 Id. at *1, *3-*18, *37.
31 See David Olson & Stefania Fusco, Rules Versus Standards: Competing Notions of
Inconsistency Robustness in Patent Law, 64 ALA. L. REV. 647, 666-68, 666 n.91 (2013) (addressing
the history of the Supreme Court’s interpretation of 35 U.S.C. § 103).
32 Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc., 933 F.3d 1367, 1375 (Fed. Cir. 2019).
33 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *5-*11, *37.
34 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1370.
26
27
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Next, Part II introduces the nonobviousness requirement imposed by the
Supreme Court. Part III describes the evolution of the lead compound analysis
specifically for determining whether a pharmaceutical compound patent is obvious.
Part IV discusses the Sanofi-Aventis decision, including the technical background,
key prior art references, Federal Circuit’s reasoning, and implications drawn from
the case. Last, Part V argues that the Sanofi-Aventis approach is beneficial to
patenting activities of ongoing drug development among competing research groups.
II. 35 U.S.C. § 103, GRAHAM AND KSR
There are two important Supreme Court decisions defining the contour of the
nonobviousness requirement.35 In 1966, the Supreme Court in Graham v. John Deere
Company instructed lower courts to evaluate four factors to determine whether a
claim is obvious: (1) “the scope and content of the prior art”; (2) “differences between
the prior art and the claims at issue”; (4) “the level of ordinary skill in the pertinent
art”; and (4) “secondary considerations as commercial success, long felt but unsolved
needs, failure of others, etc.”36
In 2007, the Supreme Court in KSR International Co. v. Teleflex Inc.37 examined
the Federal Circuit’s teaching/suggestion/motivation (“TSM”) test for the
nonobviousness requirement.38 Under the TSM test, “a patent claim is only proved
obvious if ‘some motivation or suggestion to combine the prior art teachings’ can be
found in the prior art, the nature of the problem, or the knowledge of a person having
ordinary skill in the art.’”39 However, the KSR Court criticized that the TSM test was
too rigid to comply with its precedents.40
To reject the Federal Circuit’s rigid approach, the KSR Court started with its
precedents before and after 35 U.S.C. § 103 was enacted. 41 Eventually, the KSR
Court laid down several principles for determining “whether a patent claiming the
combination of elements of prior art is obvious.”42 First, “[w]hen a work is available
in one field of endeavor, design incentives and other market forces can prompt
35 See Laura G. Pedraza-Fariña & Ryan Whalen, A Network Theory of Patentability, 87 U. CHI.
L. REV. 63, 81-82 (2020) (analyzing Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966), and
KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007)).
36 Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 17-18 (1966); see also Insite Vision Inc.
v. Sandoz, Inc., 783 F.3d 853, 858 (Fed. Cir. 2015) (quoting Graham, 383 U.S. at 17); see also Briana
Barron, Structural Uncertainty: Understanding the Federal Circuit’s Lead Compound Analysis, 16
MARQ. INTELL. PROP. L. REV. 401, 402 (2012) (discussing Graham).
37 KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 398-428 (2007).
38 See Mark D. Janis, Tuning the Obviousness Inquiry After KSR, 7 WASH. J.L. TECH. & ARTS
335, 342 (2012) (discussing the Federal Circuit’s response to the Supreme Court’s Decision in KSR
International Co.).
39 KSR Int’l Co., 550 U.S. at 407.
40 Id. at 419.
41 Id. at 415-17.
42 KSR Int’l Co., 550 U.S. at 417; see also Katherine M. L. Hayes, Three Years Post-KSR: A
Practitioner’s Guide to “Winning” Arguments on Obviousness and a Look at What May Lay Ahead, 9
NW. J. TECH. & INTELL. PROP. 243, 246-48 (2010) (discussing five observations made by the KSR
Court with regard to the obviousness analysis).
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variations of it, either in the same field or a different one.” 43 Therefore, if a
predictable variation can be implemented by a person of ordinary skill, it is likely
unpatentable under § 103.44 Similarly, “if a technique has been used to improve one
device, and a person of ordinary skill in the art would recognize that it would
improve similar devices in the same way, using the technique is obvious unless its
actual application is beyond his or her skill.”45 The ultimate question is “whether the
improvement is more than the predictable use of prior art elements according to their
established functions.”46
The KSR Court acknowledged that these principles may be more difficult to
apply.47 The KSR Court instructed that:
a court to look to interrelated teachings of multiple patents; the
effects of demands known to the design community or present in the
marketplace; and the background knowledge possessed by a person
having ordinary skill in the art, all in order to determine whether
there was an apparent reason to combine the known elements in the
fashion claimed by the patent at issue.48
In addition, the KSR Court required that the obviousness analysis “should be made
explicit[,]” but courts “need not seek out precise teachings directed to the specific
subject matter of the challenged claim, for a court can take account of the inferences
and creative steps that a person of ordinary skill in the art would employ.”49
Furthermore, the KSR Court clarified that in determining whether a claim is
obvious, the objective reach of the claim matters, but the particular motivation or
avowed purpose of the patentee doesn’t.50 Thus, a claim “can be proved obvious [] by
noting that there existed at the time of invention a known problem for which there
was an obvious solution encompassed by the claim].”51
From this aspect, the KSR Court offered additional principles.52 First, “any need
or problem known in the field of endeavor at the time of invention and addressed by
the patent can provide a reason for combining the elements in the manner claimed.”53
Second, “[a] person of ordinary skill is also a person of ordinary creativity, not [the
claimed technical solution].” 54 Third, “[w]hen there is a design need or market
pressure to solve a problem and there are a finite number of identified, predictable
solutions, a person of ordinary skill has good reason to pursue the known options

KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 417 (2007).
Id. at 417.
45 Id.
46 Id.
47 KSR Int’l Co., 550 U.S. at 417.
48 Id. at 418 (emphasis added).
49 KSR Int’l Co., 550 U.S. at 417.
50 See id. at 419.
51 Id. at 419-20.
52 See id. at 419-22.
53 KSR Int’l Co., 550 U.S. at 420 (emphasis added).
54 Id. at 421.
43
44
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within his or her technical grasp.”55 If the success of pursuing a known option would
have been anticipated, “the fact that a combination was obvious to try might show
that [the combination] was obvious under § 103.”56
Finally, while cautioning that “[a] factfinder should be aware, of course, of the
distortion caused by hindsight bias and must be cautious of arguments reliant upon
ex post reasoning[,]” the KSR Court rejected “[r]igid preventative rules that deny
factfinders recourse to common sense” because such rules “are neither necessary
under [its] case law nor consistent with it.”57
III. LEAD COMPOUND ANALYSIS FOR PHARMACEUTICAL COMPOUND PATENTS
A. Early Development
The idea of “lead compound” in the context of analyzing the nonobviousness
requirement of pharmaceutical compound claims first came to the Federal Circuit in
Yamanouchi Pharmaceutical Co., Ltd. v. Danbury Pharmacal, Inc.58 The patented
compound there was famotidine used for inhibiting production of stomach acid to
treat heartburn and ulcers.59 The defendant alleged that two lead compounds would
have been selected by one of skill in the art to form the claimed compound.60
Under four Graham factual factors,61 the Yamanouchi court stated that “[f]or a
chemical compound, a prima facie case of obviousness requires ‘structural similarity
between claimed and prior art subject matter . . . where the prior art gives reason or
motivation to make the claimed compositions.’” 62 The court also required “a
reasonable expectation of success, not absolute predictability” to support a conclusion
of obviousness.63 Ultimately, the court framed the obviousness issue as “whether one
of skill in this art would have found motivation to combine pieces from one compound

Id. at 417.
Id. (emphasis added).
57 Id.
58 Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc., 231 F.3d 1339, 1339-1348 (Fed. Cir.
2000); see Briana Barron, Structural Uncertainty: Understanding the Federal Circuit’s Lead
Compound Analysis, 16 MARQ. INTELL. PROP. L. REV. 401, 405 (2012) (“The earliest case
establishing the modern ‘lead compound’ analysis is Yamanouchi Pharm. Co. v. Danbury Pharmacal,
Inc.”).
59 Yamanouchi Pharm. Co., 231 F.3d at 1341.
60 Yamanouchi Pharm. Co., 231 F.3d at 1343-44; see also Appellants’ Brief at 11-12,
Yamanouchi Pharm. Co., 231 F.3d 1339 (Fed. Cir. 2000) (Nos. 99-1521, 99-1522), 1999 WL 33631182
(“There is a common medicinal research technique known as ‘lead-following’. When a particular new
compound is known to be especially active for a particular intended use, a ‘lead’ compound,
medicinal chemists modify the structure of the ‘lead’ compound slightly to produce another
compound which is also expected to be active for the same use but is hoped to have improved
pharmacological properties and fewer deficiencies.”).
61 Yamanouchi Pharm. Co., 231 F.3d at 1343.
62 Id. (quoting In re Dillon, 919 F.2d 688, 692 (Fed.Cir.1990) (en banc)).
63 See id. (quoting In re Longi, 759 F.2d 887, 896 (Fed.Cir.1985)).
55
56
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in a prior art patent with a piece of another compound in the second prior art patent
through a series of manipulations.”64
In Eli Lilly and Co. v. Zenith Goldline Pharmaceuticals, Inc., the Federal Circuit
again reviewed the defendant’s argument that the district court clearly erred in
requiring evidence of “a teaching or incentive to treat the closest prior art (i.e.,
Compound ’222[, later known as ethyl olanzapine]) as a ‘lead compound.’” 65 The
patented compound was olanzapine used for treating schizophrenia.66 The difference
of olanzapine and Compound ’222 was the ethyl substitution in Compound ’222.67
The Eli court’s nonobviousness analysis followed the “structural similarity”
approach adopted the Yamanouchi court.68 Further, the Eli court added two aspects
that may negate obviousness.69 First, “patentability for a chemical compound does
not depend only on structural similarity.” 70 Second, “[the] court will not ignore a
relevant property of a compound in the obviousness calculus.” 71 That is, “[w]hen
claimed properties differ from the prior art, those differences, if unexpected and
significant, may lead to nonobviousness.”72 Finally, the Eli court agreed with the
district court’s nonobviousness decision, because the evidence showed “the state of
the art would have directed the person of ordinary skill in the art away from
unfluorinated compounds like Compound ’222.”73
B. Post-KSR Development
Takeda Chemical Industries, Ltd. v. Alphapharm Pty., Ltd. was the Federal
Circuit’s first post-KSR decision where the defendant argued compound b would have
been selected as a lead compound for making the patented compound, pioglitazone,
used for treating Type 2 diabetes.74
The Takeda court held that KSR International Co. affirmed that the Graham
factual factors still controls the nonobviousness analysis.75 Under KSR International
Co., the Takeda court advanced the “structural similarity” approach in several
aspects.76 First, the court stated that “a prima facie case of obviousness also requires
a showing of ‘adequate support in the prior art’ for the change in structure.”77

Yamanouchi Pharm. Co., 231 F.3d at 1343.
Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 471 F.3d 1369, 1377 (Fed. Cir. 2006).
66 Id. at 1373.
67 Id. at 1375.
68 Id. at 1377.
69 Id. at 1378.
70 Eli Lilly & Co., 471 F.3d at 1378.
71 Eli Lilly & Co., 471 F.3d at 1377 (emphasis added).
72 Id.
73 Id. at 1379 (emphasis added).
74 Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1352-54, 1356-57 (Fed.
Cir. 2007); see also Dean L. Fanelli et. al., 2007 Patent Law Decisions of the Federal Circuit, 57 AM.
U. L. REV. 821, 926 (2008) (analyzing Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd.).
75 See Takeda Chem. Indus., Ltd., 492 F.3d at 1355.
76 Id. at 1356.
77 Id. (emphasis added) (citing In re Grabiak, 769 F.2d 729, 731-32 (Fed. Cir.1985)).
64
65
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Second, the Takeda court revisited its precedent and reaffirmed a precedential
notion that “[n]ormally a prima facie case of obviousness is based upon structural
similarity, i.e., an established structural relationship between a prior art compound
and the claimed compound.” 78 The court reasoned that “close or established
‘[s]tructural relationships may provide the requisite motivation or suggestion to
modify known compounds to obtain new compounds.’”79
Third, the Takeda court stated that “[a] known compound may suggest its
homolog, analog, or isomer[.]”80 The court reasoned that “such compounds ‘often have
similar properties and therefore chemists of ordinary skill would ordinarily
contemplate making them to try to obtain compounds with improved properties.’”81 In
addition, the court emphasized that in such instances, “a showing that the ‘prior art
would have suggested making the specific molecular modifications necessary to
achieve the claimed invention’ was also required.”82
Finally, the Takeda court concluded that under KSR International Co., “in cases
involving new chemical compounds, it remains necessary to identify some reason that
would have led a chemist to modify a known compound in a particular manner to
establish prima facie obviousness of a new claimed compound.”83
While the Takeda court focused on the finding of a “known compound,” it
learned from the defendant that a “lead compound” is “a compound in the prior art
that would be most promising to modify in order to improve upon its antidiabetic
activity and obtain a compound with better activity.”84 Eventually, the Takeda court
upheld the district court’s nonobviousness determination, because the defendant:
failed to adduce evidence that compound b would have been selected
as the lead compound and, even if that preliminary showing had been
made, [the defendant] failed to show that there existed a reason,
based on what was known at the time of the invention, to perform the
chemical modifications necessary to achieve the claimed compounds.85
In Eisai Co. v. Dr. Reddy’s Laboratories, Ltd., the Federal Circuit recognized the
“structural similarity” approach as “the analysis of the third Graham factor (the
differences between the claimed invention and the prior art)” and stated that the
analysis “often turns on the structural similarities and differences between the
claimed compound and the prior art compounds.” 86 In addition, while requiring
Id. (quoting In re Deuel, 51 F.3d 1552, 1558 (Fed.Cir.1995)) (alteration in original).
Id. (quoting Deuel, 51 F.3d at 1558) (alteration in original and emphasis added).
80 Takeda Chem. Indus., Ltd., 492 F.3d at 1356.
81 Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1355 (Fed. Cir. 2007)
(quoting Deuel, 51 F.3d at 1558).
82 Id. (quoting Deuel, 51 F.3d at 1558) (emphasis added).
83 Id. at 1356-57 (emphasis added).
84 Id. at 1357.
85 Takeda Chem. Indus., Ltd., 492 F.3d at 1362-63 (emphasis added).
86 Eisai Co. v. Dr. Reddy’s Labs., Ltd., 533 F.3d 1353, 1356-57 (Fed. Cir. 2008); see also Scott D.
Locke & William D. Schmidt, Protecting Pharmaceutical Inventions in A KSR World, 50 IDEA 1, 16
(2009) (introducing Eisai Co. v. Dr. Reddy’s Labs., Ltd., 533 F.3d 1353 (Fed. Cir. 2008)). See Takeda
Chem. Indus., Ltd., 492 F.3d at 1355 (the Federal Circuit discussed the “structural similarity”
approach under the headline of “Differences Between the Prior Art and the Claims”).
78
79
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identification of a reason to modify a known compound, the Eisai court referred to
“known compound” as “lead compound.”87
Furthermore, the Eisai court reminded that under KSR International Co., “the
requisite motivation can come from any number of sources and need not necessarily
be explicit in the art.”88 Thus, the court held that “it is sufficient to show that the
claimed and prior art compounds possess a ‘sufficiently close relationship . . . to
create an expectation,’ in light of the totality of the prior art, that the new compound
will have ‘similar properties’ to the old.”89
Takeda Chemical Industries, Ltd. and Eisai Co. were later followed by Altana
Pharma AG v. Teva Pharmaceuticals USA, Inc.90 and Daiichi Sankyo Co. v. Matrix
Laboratories, Ltd.91 The Daiichi court further required the level of an ordinary skill
in the art be a “medicinal chemist of ordinary skill” rather than a “chemist of
ordinary skill.”92
Finally, in Unigene Laboratories, Inc. v. Apotex, Inc., the Federal Circuit further
transformed the term “known compound” into “lead compound,” when it developed a
nonobviousness analysis for a drug formulation claim from the “structural similarity”
approach.93 The court stated that “[a] prima facie case of obviousness in the chemical
arts is often based on a known compound, called a ‘lead compound[.]’”94 The court
also defined a lead compound as something that “serves as a starting point for a
person of ordinary skill developing the claimed invention” and “is often used to show
structural similarities between the claimed compound and prior art.”95
C. Two-Part Inquiry: Otsuka Pharmaceutical Co. v. Sandoz, Inc.
A line of cases after Takeda Chemical Industries, Ltd. shows that the Federal
Circuit focused on whether a known or lead compound would have been modified to
make the claimed compound, which is a single inquiry. 96 However, in 2012, the
Federal Circuit in Otsuka Pharmaceutical Co. v. Sandoz, Inc. framed the lead
compound analysis as a two-step analysis for the nonobviousness requirement of a
new chemical compound.97
The Otsuka Pharmaceutical Co. court stated that “[o]ur case law demonstrates
that whether a new chemical compound would have been prima facie obvious over

See Eisai Co., 533 F.3d at 1357.
Id. (citing Aventis Pharma Deutschland GmbH v. Lupin, Ltd., 499 F.3d 1293, 1301 (Fed. Cir.
2007)).
89 Id. (quoting Aventis Pharma Deutschland GmbH, 499 F.3d at 1301).
90 Altana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 999, 1007 (Fed. Cir. 2009) (upholding
the district court’s denial of the plaintiff’s motion for preliminary injunction).
91 Daiichi Sankyo Co. v. Matrix Labs., Ltd., 619 F.3d 1346, 1352 (Fed. Cir. 2010).
92 Id.
93 Unigene Labs., Inc. v. Apotex, Inc., 655 F.3d 1352, 1361 (Fed. Cir. 2011).
94 Id. (citing Eisai Co., 533 F.3d at 1357).
95 Id. (citing Eisai Co., 533 F.3d at 1357).
96 See supra Part III.B.
97 See Robert J. Smyth et. al., 2012 Patent Law Decisions of the Federal Circuit, 62 AM. U. L.
REV. 827, 859 (2013) (briefing Otsuka Pharm. Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012)).
87
88
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particular prior art compounds ordinarily follows a two-part inquiry.” 98 The first
question asks “whether a chemist of ordinary skill would have selected the asserted
prior art compounds as lead compounds, or starting points, for further development
efforts.”99 The second question is “whether the prior art would have supplied one of
ordinary skill in the art with a reason or motivation to modify a lead compound to
make the claimed compound with a reasonable expectation of success.”100
Regarding step one, the Otsuka Pharmaceutical Co. court described the nature
of a lead compound in two aspects.101 First, a lead compound is “a compound in the
prior art that would be most promising to modify in order to improve upon its . . .
activity and obtain a compound with better activity.”102 Second, a lead compound is
“a natural choice for further development efforts.”103
In addition, the Otsuka Pharmaceutical Co. court stated that when the parties
disputes “the notion that a chemist must select one or more lead compounds[,]” step
one analysis “focuses on those proposed lead compounds that the alleged infringer
has attempted to prove, by clear and convincing evidence, that the skilled artisan
would have had a reason to select from the panoply of known compounds in the prior
art.” 104 From this aspect, the court emphasized that “the analysis is guided by
evidence of the compound’s pertinent properties [that] may include positive
attributes such as activity and potency; adverse effects such as toxicity and other
relevant characteristics in evidence.”105
Furthermore, the Otsuka Pharmaceutical Co. court cautioned that “[a]bsent a
reason or motivation based on such prior art evidence, mere structural similarity
between a prior art compound and the claimed compound does not inform the lead
compound selection.” 106 This caution may help avoid impermissible ex post
reasoning.107
As for step two, the Otsuka Pharmaceutical Co. court stated that “the reason or
motivation for modifying a lead compound may come from any number of sources and
need not necessarily be explicit in the prior art.”108 In addition, the court offered two
evidentiary aspects of finding a reason or motivation.109 First, the court noted that “it
is the possession of promising useful properties in a lead compound that motivates a
chemist to make structurally similar compounds.”110 Thus, step two still considers

Otsuka Pharm. Co. v. Sandoz, Inc., 678 F.3d 1280, 1291 (Fed. Cir. 2012) (emphasis added).
Id. (citing Eisai Co., 533 F.3d at 1359).
100 Id. at 1292 (emphasis added).
101 See id. at 1291.
102 Id. (quoting Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1357 (Fed.
Cir. 2007)).
103 Otsuka Pharm. Co., 678 F.3d at 1291 (quoting Altana Pharma AG v. Teva Pharm. USA, Inc.,
566 F.3d 999, 1008 (Fed. Cir. 2009)).
104 Id. at 1292.
105 Id. (international citations omitted).
106 Id.
107 See id.
108 Otsuka Pharm. Co., 678 F.3d at 1292.
109 Otsuka Pharm. Co., 678 F.3d at 1292-93.
110 Id. at 1292-93 (emphasis added) (quoting Daiichi Sankyo Co. v. Matrix Labs., Ltd., 619 F.3d
1346, 1354 (Fed. Cir. 2010)).
98
99
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the compound’s pertinent properties.111 Second, the court held that “it is sufficient to
show that the claimed and prior art compounds possess a ‘sufficiently close
relationship . . . to create an expectation,’ in light of the totality of the prior art, that
the new compound will have ‘similar properties’ to the old.”112
D. Post-Otsuka Development
The two-part analysis under Otsuka Pharmaceutical Co. has not become a
standard of the Federal Circuit,113 except for Pfizer Inc. v. Teva Pharmaceuticals USA,
Inc.114 and, arguably, Bristol-Myers Squibb Co. v. Teva Pharmaceuticals USA, Inc.115
Those latter cases not following the two-part inquiry can be divided into two
categories. The first category includes In re Rosuvastatin Calcium Patent
Litigation,116 where the district court’s decision on the defendant’s “lead compound”
argument came before Otsuka Pharmaceutical Co.117 Relying on the single inquiry
under Takeda Chemical Industries, Ltd., the Federal Circuit upheld the district
court’s finding that the asserted prior art compound would not have been selected as
a lead compound or modified to make the patented compound.118
The second category includes Millennium Pharmaceuticals, Inc. v. Sandoz
Inc., 119 Amerigen Pharmaceuticals Limited v. UCB Pharma GmBH, 120 and SanofiAventis U.S., LLC v. Dr. Reddy’s Laboratories, Inc., 121 where the issue on appeal
focused on whether the selected lead compound would have been modified to make

See id. at 1292.
Id. at 1293 (emphasis added) (quoting Aventis Pharma Deutschland GmbH v. Lupin, Ltd.,
499 F.3d 1293, 1301 (Fed. Cir. 2007) (determining whether a claimed compound is obvious because
it is a purified form of a prior-art mixture)).
113 See, e.g., In re Rosuvastatin Calcium Patent Litig., 703 F.3d 511, 511-529 (Fed. Cir. 2012);
Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc., 752 F.3d 967, 967-979 (Fed. Cir. 2014);
Millennium Pharm., Inc. v. Sandoz Inc., 862 F.3d 1356, 1356-1370 (Fed. Cir. 2017); Amerigen
Pharm. Ltd. v. UCB Pharma GmBH, 913 F.3d 1076, 1076-1089 (Fed. Cir. 2019).
114 See Pfizer Inc. v. Teva Pharm. USA, Inc., 555 F. App’x 961, 969-70 (Fed. Cir. 2014).
115 See Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc., 752 F.3d 967, 972-76 (Fed. Cir.
2014) (without referring to the two-part inquiry, upholding the district court’s finding that “a skilled
artisan would have selected 2’-CDG as a lead compound and made the minor modification to arrive
at entecavir.”). See Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc., 923 F. Supp. 2d 602, 654 (D.
Del. 2013) (district court’s obviousness determination followed the two-part inquiry under Otsuka
Pharmaceutical Co).
116 In re Rosuvastatin Calcium Patent Litig., 703 F.3d 511, 511-529 (Fed. Cir. 2012).
117 See In re Rosuvastatin Calcium Patent Litig., 719 F. Supp. 2d 388, 388, 405 (D. Del. 2010),
as revised (July 1, 2010) (“According to Defendants, Compound lb does not need to be shown to be
the only possible starting point or the ‘lead compound’ in the development of rosuvastatin, but
rather, that Compound lb would have been an obvious and suitable starting point from which to
begin the development of rosuvastatin.”); see also In re Rosuvastatin, 703 F.3d. at 516.
118 See In re Rosuvastatin, 703 F.3d. at 517-18 (citing Takeda Chem. Indus., Ltd. v. Alphapharm
Pty., Ltd., 492 F.3d 1350, 1357 (Fed. Cir. 2007)).
119 Millennium Pharm., Inc. v. Sandoz Inc., 862 F.3d 1356, 1356-1370 (Fed. Cir. 2017).
120 Amerigen Pharm. Ltd. v. UCB Pharma GmBH, 913 F.3d 1076, 1076-1089 (Fed. Cir. 2019).
121 Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc., 933 F.3d 1367, 1367-1380 (Fed. Cir.
2019).
111
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the claimed compound.122 But, the Millennium court followed Otsuka Pharmaceutical
Co.,123 while the Amerigen court and Sanofi-Aventis court followed Takeda Chemical
Industries, Ltd.124
E. Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Laboratories, Inc.
In Sanofi-Aventis U.S., LLC, the district court impliedly applied the two-part
inquiry by holding:
[A] POSA [(person of ordinary skill in the art)] would have selected either
docetaxel or paclitaxel as a lead compound, which does not foreclose
Defendants’ ease. Defendants, however, failed to demonstrate that a POSA
would have been motivated to simultaneously modify docetaxel with a
methyl ether at the [C7] and [C10] positions to arrive at cabazitaxel.125
On appeal, the Federal Circuit seemed to go back to the single inquiry under
Takeda Chemical Industries, Ltd. by quoting: “[I]n cases involving new chemical
compounds, it remains necessary to identify some reason that would have led a
chemist to modify a known compound in a particular manner to establish prima facie
obviousness of a new claimed compound.” 126 Thus, it is sufficient to say that the
uniform standard for the nonobviousness requirement of a pharmaceutical compound
is not settled.

122 See, e.g., Millennium Pharm., Inc., 862 F.3d at 1364 (“The parties agree that bortezomib is
the proper lead compound for this analysis.”); Amerigen Pharm. Ltd., 913 F.3d at 1080 (“In its
obviousness analysis, the Board accepted that a person of ordinary skill would have chosen 5-HMT
as a lead compound for development . . . . However . . . the Board found that a person of ordinary
skill would not have been motivated to modify 5-HMT to make a prodrug[.]”); see also Sanofi-Aventis
U.S., LLC, 933 F.3d at 1375 (“The court found that a person of ordinary skill would have selected
docetaxel as a lead compound, and the key issue was thus whether a skilled artisan would have been
motivated to replace the C7 and C10 hydroxyl groups of docetaxel with the methoxy groups of
cabazitaxel.”).
123 See Millennium Pharm., Inc., 862 F.3d at 1364 (quoting Otsuka Pharm. Co., 678 F.3d at
1292).
124 See, e.g., Amerigen Pharm. Ltd., 913 F.3d at 1089 (quoting Takeda Chem. Indus., Ltd., 492
F.3d at 1356); Sanofi-Aventis U.S., LLC, 933 F.3d at 1375 (quoting Takeda Chem. Indus., Ltd., 492
F.3d at 1357).
125 Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG, 2018 WL
9364037, at *11 (D.N.J. Apr. 25, 2018).
126 Sanofi-Aventis U.S., LLC, 933 F.3d at 1375 (quoting Takeda Chem. Indus., Ltd., 492 F.3d at
1357).
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IV. ANALYSIS OF SANOFI-AVENTIS U.S., LLC V. DR. REDDY’S LABORATORIES, INC.
A. Patented Technology
Around 1989, Sanofi-Aventis’ scientists used paclitaxel and docetaxel as
reference compounds to develop taxane analogs that work as well as docetaxel in
treating sensitive tumors and have better activity than docetaxel in confronting
resistant tumors.127 The desired taxane analogs were expected to be more soluble in
water.128
The development involved modifications to the side chain at C13 position and
the core at C2, C4, C5, C6, C7, C9 and C10 positions by adding different functional
groups and changing the stereochemistry of different portions of, for example,
docetaxel.129 It took days or months to complete a successful synthesis of a certain
compound.130
A newly-synthesized compound was examined by a series of in vitro and in vivo
tests.131 The first test was an in vitro tubulin polymerization assay for determining
whether a compound acts as a taxane.132 The second test was an in vitro cellular
assay for assessing a compound’s potency in sensitive and resistant tumor cell lines
by comparing the performance of candidate compounds and docetaxel in each cell
line.133 The last test was an in vivo animal test for understanding the activity of a
candidate compound in mice bearing tumors treated with docetaxel. 134 After the
researchers, including the three inventors of the ’170 Patent, reviewed the test data,
they would decide which new compounds should move forward.135
Cabazitaxel was not a successful candidate in the beginning because of
unsuccessful modifications to C7 and C10 positions in docetaxel.136 Rather, larotaxel
(shown in Figure 3(a)) was the first candidate for further development.137 Larotaxel
discovered in January 1994 was made by replacing the hydroxyl groups at C7 and
C10 positions of docetaxel with a cyclopropane structure (shown in Figure 3(b)) at C7,
See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *4.
See id.
129 See id.
130 See id.
131 See id. at *5.
132 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *5; see also CYTOSKELETON, INC.,
TUBULIN POLYMERIZATION ASSAY KIT (CAT. # BK006P) 5-7, https://www.cytoskeleton.com/pdfstorage/datasheets/bk006p.pdf (last visited Apr. 3, 2020). A tubulin polymerization assay is based on
a scientific observation that “light is scattered by microtubules to an extent that is proportional to
the concentration of microtubule polymer.” Because “[c]ompounds or proteins that interact with
tubulin will often alter one or more of the characteristic phases of polymerization[,]”a lightscattering measurement of the concentration of microtubule polymer can indicate whether a
compound may act as an anti-cancer agent.
133 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *5; see also Bouchard, supra note 17, at
328-30.
134 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *5.
135 See id.
136 See id.
137 See id.
127
128
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C8, and C19 positions and an acetic acid functional group, respectively. 138 The
cyclopropane structure resulted in better performance in those three tests.139

(a) Larotaxel

(b) Cyclopropane
Figure 3

Before cabazitaxel was discovered, some docetaxel derivatives had been
synthesized, for instance, one derivative with a methoxy group at C10 position and
one derivative with an acetoxy group at C10 position. 140 However, the docetaxel
derivative with a C10 acetoxy group was found to perform well in those in vitro or in
vivo tests.141 Eventually, on November 15, 1994, two methoxy groups were added
onto C7 and C10 positions for the first time to complete the synthesis of
cabazitaxel.142 Among more than 450 compounds being synthesized and tested, only
larotaxel and cabazitaxel entered into human studies.143
B. Relevant Prior Arts
The district court’s nonobviousness decision was rested on seven witnesses and
seventeen prior art references.144 But, only nine references were introduced by the
Federal Circuit.145 They include:
(1) Hait’s article 146 : Hait’s research studied how phenothiazines (shown in
Figure 4(a)) affect Pgp and showed that the increase of lipophilicity of phenothiazines
See id.; see Bouchard, supra note 17, at 325.
See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *5.
140 See id.
141 See id.
142 See id.; see Bouchard, supra note 17, at 325-28.
143 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *5.
144 See Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc., 933 F.3d 1367, 1375 (Fed. Cir. 2019).
145 See id. at 1375-77.
146 See id. at 1376 n.5 (citing William N. Hait & Dana T. Aftab, Rational Design and PreClinical Pharmacology of Drugs for Reversing Multidrug Resistance, 43(1) BIOCHEMICAL
PHARMACOLOGY 103, 103-07 (1992)); see also Fresenius Kabi USA, LLC, 2018 WL 9364037, at *9.
138
139
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improves the sensitivity of a cancer cell line.147 However, the district court found that
phenothiazines were structurally quite different from taxanes and that nothing in
Hait’s article discussed the effect of taxanes on Pgp.148 In addition, the district court
found that Hait’s research merely provided a hypothetical model of Pgp binding
based on the binding phenomenon of a different protein.149
(2) Lampidis’ article 150 : Lampidis’ research indicated that the ability of
positively-charged rhodamine dyes (shown in Figure 4(b)) to accumulate in, and
eventually kill, drug-resistant cells gets better as their lipophilicity increases. 151
However, the district court found that Lampidis’ article did not mention taxanes and
that taxanes did not have a positive charge.152

(a) Phenothiazine

(b) Rhodamine
Figure 4

(3) Commerçon’s article153: Commerçon’s article was written by scientists from
RPR to report the impact on antimitotic activity caused by changes at certain
positions on the taxane core.154 Specifically, the article showed C’2, C’3, C7, C9 and
C10 positions on paclitaxel could be modified.155

See Sanofi-Aventis U.S., LLC, 933 F.3d at 1376.
See id.
149 See id.
150 See id. at 1376 n.6 (citing Theodore J. Lampidis et al., Relevance of the Chemical Charge of
Rhodamine Dyes to Multiple Drug Resistance, 38(23) BIOCHEMICAL PHARMACOLOGY 4267, 4267-71
(1989)); see also Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG,
2018 WL 9364037, at *10 (D.N.J. Apr. 25, 2018).
151 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1376; see also Fresenius Kabi USA, LLC, 2018 WL
9364037, at *10.
152 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1376.
153 See id. at 1376 n.7 (citing A. Commerçon et al., Practical Semisynthesis and Antimitotic
Activity of Docetaxel and Side-Chain Analogues, 583 TAXANE ANTICANCER AGENTS: BASIC SCIENCE
AND CURRENT STATUS 233, 233-46 (G. I. Georg et al. eds., 1994)); see also Fresenius Kabi USA, LLC,
2018 WL 9364037, at *8.
154 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *8.
155 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1376.
147
148
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(4) Kingston’s article156: Kingston’s article provided what chemical modifications
are tolerated at each position on taxane core.157
(5) Golik’s patent158: Golik’s European patent was filed by BMS.159 Golik’s patent
disclosed some paclitaxel derivatives made by replacing the hydroxyl group at C7
position with a methylthiomethoxyl group (namely, 7-O-methylthiomethyl).160 In an
in vitro cellular test, one 7-O-methylthiomethyl paclitaxel derivative showed
increased activity than paclitaxel and docetaxel.161 However, the district court found
that the modification of C7 position with a methylthiomethoxyl group could not lead
to a methoxy substitution at the same position.162
(6) Ojima’s article 163 : Ojima’s article was co-authored by researchers from
RPR.164 The article taught that some substitutions at C’3 position produced much
better activity than paclitaxel and docetaxel against a drug-resistant cell line. 165
Nothing about a methoxy substitution at C7 or C10 position was mentioned in the
article.166 Finally, the district court found that the article did not suggest increasing
lipophilicity of C7 and C10 positions to against drug resistant cells.167
(7) Wong’s patent 168 : Wong’s U.S. patent was filed by BMS. 169 The patent
disclosed a paclitaxel derivative with a methoxy at C7 position. 170 However, the
district court found that the patent provided a more promising paclitaxel derivative
with a modification at C’2 position and a different ether substitution at C7
position. 171 In addition, the court found that the patent did not disclose any
compound with a hydroxy or methoxy at C10 position like docetaxel or cabazitaxel
and any activity data from drug-resistant cell line tests.172

156 See id. at 1376 n.8 (citing David G. I. Kingston, Recent Advances in the Chemistry and
Structure-Activity Relationships of Paclitaxel, 583 TAXANE ANTICANCER AGENTS: BASIC SCIENCE
AND CURRENT STATUS 203, 203-216 (G. I. Georg et al. eds., 1994)); see also Fresenius Kabi USA, LLC,
2018 WL 9364037, at *9-*10.
157 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *10.
158 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1376 (introducing European Patent No.
0,639,577); see also Fresenius Kabi USA, LLC, 2018 WL 9364037, at *8.
159 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *8; see also European Patent No.
0,639,577 front page.
160 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1376; see also ’577 European Patent ¶¶ 0011,
0194-0198.
161 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1376.
162 See id. at 1376-77.
163 See id. at 1377 n.9 (citing Iwao Ojima et al., Syntheses and Structure-Activity Relationships
of New Taxoids, 583 TAXANE ANTICANCER AGENTS: BASIC SCIENCE AND CURRENT STATUS 262 (G. I.
Georg et al. eds., 1994)); see Fresenius Kabi USA, LLC, 2018 WL 9364037, at *10.
164 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *10.
165 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377.
166 See id.
167 See id.
168 See id. at 1377 (discussing U.S. Patent No. 6,201,140 (filed Mar. 13, 2001)); see also
Fresenius Kabi USA, LLC, 2018 WL 9364037, at *11.
169 See U.S. Patent No. 6,201,140 (filed Mar. 13, 2001).
170 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377; see also ‘140 Patent col. 22 (examples 1 & 2),
col. 23 (example 5).
171 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377.
172 See id.
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(8) Kant’s paper 173 : Kant’s paper reported the results of taxane research at
BMS.174 The research focused on modifications at C10 position, including a methoxy
substitution leading to a docetaxel-like compound with a methoxy at C10 position.175
Modifications at C7 position were not studied.176 All synthesized compounds were
only tested with an in vitro tubulin polymerization assay. 177 However, the C10methoxy docetaxel derivative was compared only to paclitaxel, not docetaxel.178 The
test result of the C10-methoxy docetaxel derivative was good, but another compound
showed better performance.179
(9) Klein’s paper 180 : The paper focused on modifications at C9 position and
reported that some synthesized samples had better water solubility and stability
than paclitaxel and showed excellent activity in an in vitro tubulin polymerization
assay.181 Among those synthesized compounds with better activity was a compound
with a methoxy at C7 position. 182 However, the paper did not mention any
modification at C10 position or any test data from tumor cell lines.183
Specifically, the Federal Circuit’s nonobviousness holding was based on Hait’s
article, Lampidis’ article, Commerçon’s article, Ojima’s article, and Golik’s patent.184
C. Federal Circuit’s Reasoning
On appeal, the appellant/defendant argued that the district court erred in
rejecting its obviousness theory that “a skilled artisan would have: (1) been
motivated to modify docetaxel to reduce Pgp-related drug resistance; (2) knew that
this could be accomplished by increasing lipophilicity of the C7 and C10 positions;
and (3) determined that methoxy substitutions were the ‘smallest, most conservative’
modification to achieve that goal.” 185 But, the Federal Circuit sided with the
appellee/patentee and held the argument was hindsight-driven.186
173 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377 n.10 (citing Joydeep Kant et al., A
Chemoselective Approach to Functionalize the C-10 Position of 10-Deacetylbaccatin III. Synthesis and
Biological Properties of Novel C-10 Taxol® Analogues, 35 TETRAHEDRON LETTERS 5543, 5543-46
(1994)); see also Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG,
2018 WL 9364037, at *9 (D.N.J. Apr. 25, 2018).
174 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *9.
175 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377.
176 See id.
177 See Fresenius Kabi USA, LLC, 2018 WL 9364037, at *12; see also Sanofi-Aventis U.S., LLC,
933 F.3d at 1377.
178 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377.
179 See id.
180 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377 n.11 (citing L. L. Klein et al., Chemistry and
Antitumor Activity in 9(R)-Dihydrotaxanes, 583 TAXANE ANTICANCER AGENTS: BASIC SCIENCE AND
CURRENT STATUS 276, 276-87 (G. I. Georg et al. eds., 1994)); see also Fresenius Kabi USA, LLC,
2018 WL 9364037, at *11.
181 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1377.
182 See id.
183 See id.
184 See id. at 1378-80.
185 See id. at 1378.
186 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1378.
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First, the Federal Circuit agreed with the district court’s finding that Hait’s
article and Lampidis’ article “would not have provided a reason to make docetaxel
more lipophilic [to combat drug resistance].”187 The Federal Circuit found that both
references did not study taxanes but compounds structurally different from
taxanes.188 The Federal Circuit also found that a hypothetical model in Hait’s article
was neither based on real Pgp nor cited by the prior art references discussing
taxanes.189
Second, the Federal Circuit upheld the district court’s finding of no motivation to
make simultaneous methoxy substitutions at C7 and C10 positions to increase
lipophilicity of docetaxel.190 Although concluding that the prior art references showed
substitutions at many positions on taxanes,191 the Federal Circuit emphasized that
no prior art reference actually “made simultaneous substitutions of any kind at C7
and C10 [positions].” 192 Additionally, in those references disclosing individual
methoxy substitutions at C7 or C10 position, the Federal Circuit did not find any test
result from drug-resistant cell lines or any indication that drug resistance can be
overcome due to those methoxy substitutions.193 Furthermore, the Federal Circuit
criticized that the defendant mischaracterized or selectively read some prior art
references to support its allegations.194
Third, the Federal Circuit rejected the defendant’s view that simultaneous
methoxy substitutions at C7 and C10 positions would have been made “because they
are ‘small, conservative changes’ that increase lipophilicity.”195 The Federal Circuit
specifically discussed the defendant’s arguments based on Golik’s patent and Ojima’s
article and concluded that these arguments were hindsight.196
Regarding Golik’s patent, the defendant asserted that the teaching of C7
methylthiomethoxy substitutions would have supported a motivation to make a C7
methoxy substitution.197 However, the Federal Circuit found no proof that a methoxy
substitution would provide a similar benefit as a methylthiomethoxy substitution.198
The Federal Circuit also criticized that the defendant’s expert testimony on the
properties of methylthiomethoxy was vague.199
As for Ojima’s article, the defendant argued that the “implicit teaching of the
benefits of a C10 acetoxy group against drug-resistant cells” would provide a
motivation to make a methoxy substitution because methoxy “is smaller and more
conservative.” 200 However, the Federal Circuit found that the defendant failed to
provide non-conclusory evidence or persuasive explanation to show that the methoxy
Id.
Id.
189 Id.
190 Id.
191 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1378.
192 Id.
193 Id.
194 Id. at 1378-79.
195 Id. at 1379-80.
196 See Sanofi-Aventis U.S., LLC, 933 F.3d at 1379-80.
197 Id. at 1379.
198 Id.
199 See id.
200 See id.
187
188
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would be the same beneficial as the acetoxy or would serve a more conservative
choice than the acetoxy.201
Lastly, the Federal Circuit responded to the defendant’s challenge to the district
court’s decision on secondary considerations in favor of the patentee.202 The Federal
Circuit upheld the decision again, because the defendant failed to allege any error
made by the district court.203 Ultimately, the Federal Circuit held that the district
court did not err in finding “[m]ultiple groups around the world tried unsuccessfully
to develop taxanes into effective therapies and only [Sanofi] succeeded in developing
a compound that showed superior activity over docetaxel, namely cabazitaxel, and
obtained FDA approval.” 204 Therefore, the Federal Circuit affirmed the district
court’s decision that claims 1 and 2 of the ’170 Patent were not obvious in view of
those prior art references.205
D. Implication I: Motivation Based on Structural Similarity
“Structural similarity” has served as a basis for selecting a lead compound.206
The Sanofi-Aventis court further extends the “structural similarity” requirement to
modification of a lead compound. For instance, in rejecting the defendant’s
arguments related to reducing Pgp-related drug resistance, the Sanofi-Aventis court
criticized that Hait’s article “studied phenothiazines, which are much smaller than
taxanes and have a three-ring structure bearing no resemblance to taxanes.” 207
Likewise, in reviewing the defendant’s arguments about increasing lipophilicity, the
Sanofi-Aventis court pointed to the fact that Lampidis’ article “focused on positivelycharged dyes and suggested that increasing lipophilicity of positively-charged
molecules could be beneficial, but docetaxel is not positively charged.”208
The Sanofi-Aventis court also highlighted the problems of those cited references.
First, the Sanofi-Aventis court questioned that “despite the apparent interest in
taxane analogs, not a single reference relied on by [the defendant] made
simultaneous substitutions of any kind at C7 and C10.”209 Second, the Sanofi-Aventis

Sanofi-Aventis U.S., LLC, 933 F.3d at 1379-80.
Id. at 1380.
203 Id.
204 Id.
205 Id.
206 See W. Nicholson Price II, The Cost of Novelty, 120 COLUM. L. REV. 769, 786-87 (2020)
(discussing the Federal Circuit’s lead compound analysis); see also Douglas L. Rogers, Federal
Circuit’s Obviousness Test for New Pharmaceutical Compounds: Gobbledygook?, 14 CHI.-KENT J.
INTELL. PROP. 49, 83 (2014) (discussing the Federal Circuit’s decision in Otsuka Pharm. Co.); but see
Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 471 F.3d 1369, 1379 (Fed. Cir. 2006) (“And though
olanzapine is also the adjacent homolog of Compound ’222, patentability for a chemical compound
does not depend only on structural similarity. . . . When claimed properties differ from the prior art,
those differences, if unexpected and significant, may lead to nonobviousness.”).
207 Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc., 933 F.3d 1367, 1378 (Fed. Cir. 2019).
208 Id.
209 Id. at 1379.
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court found nowhere in Ojima’s article “investigated a methoxy-substituted taxane,
at C10 or anywhere else.”210
The Sanofi-Aventis approach is consistent with the Federal Circuit’s precedent.
In Takeda Chemical Industries, Ltd., the patented compound was pioglitazone, an
active ingredient of ACTOS® used for treating patients who suffer from Type 2
diabetes. 211 The asserted lead compound (compound b) had a pyridyl ring with a
methyl (CH3) group attached to the 6-position of the ring, while pioglitazone had a
pyridyl ring with an ethyl (C2H5) group attached to the 5-position of the ring. 212
Although both compound b and pioglitazone belong to the same chemical class,
thiazolidinediones, the Federal Circuit upheld the district court’s nonobviousness
conclusion.213
The question in Takeda Chemical Industries, Ltd. was whether there would have
been a motivation to “both homologate the methyl group of compound b and move the
resulting ethyl group to the 5-position on the pyridyl ring in order to obtain
pioglitazone.”214 The first and second steps were referred to as “homologation” and
“ring-walking,” respectively. 215 The district court found no expectation that ringwalking would have improved efficacy and safety.216
Among other things, the district court considered the opinion of the defendant’s
expert expressing that the patentee “knew” the ring-walking idea.217 However, the
expert opinion was based on the efficacy data of phenyl compounds in one prior art
reference (Sohda II paper).218 The defendant also failed to show that “one skilled in
the art would have understood that these results were transferable from a phenyl to
a pyridyl compound[.]”219 Thus, the district court discredited the expert opinion.220
On appeal, the Takeda court did not hold the district court’s ring-walking
findings clearly erroneous.221 Therefore, the Takeda court implied that because of the
structural difference between pyridyl and phenyl the obviousness analysis requires

Id.
Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1352 (Fed. Cir. 2007).
212 Id at 1354.
213 Id at 1355.
214 Id at 1360; see also Scott R. Conley, Irrational Behavior, Hindsight, and Patentability:
Balancing the “Obvious to Try” Test with Unexpected Results, 51 IDEA 271, 290 (2011) (“To
homologate” or “homologation” is defined as a reaction for converting a member of a chemical class
by adding a carbon atom into the targeted functional group of a compound.). See M. Röper & H.
Loevenich, The Homologation of Methanol, CATALYSIS IN C1 CHEMISTRY 105, 105 (W. Keim ed., D.
Reidel Publishing Co. 1983).
215 Takeda Chem. Indus., Ltd., 492 F.3d at 1360.
216 Id. at 1361; see also Takeda Chem. Indus., Ltd. v. Mylan Labs., Inc., 417 F. Supp. 2d 341,
381 (S.D.N.Y. 2006) (“[the defendant] has not shown that one skilled in the art would have been
motivated to move to pioglitazone by ‘walking the ring.’”).
217 Takeda Chem. Indus., Ltd., 492 F.3d at 1361.
218 See id.; see also T. Sohda et al., Studies on Antidiabetic Agents. II. Synthesis of 5–[4–(1–
Methylcyclohexylmethoxy)–benzyl]thiazolidine–2,4–dione (ADD–3878) and its Derivatives, 30 CHEM.
PHARM. BULL. 3580 (1982). See Takeda Chem. Indus., Ltd., 417 F. Supp. 2d at 350-51.
219 Takeda Chem. Indus., Ltd., 417 F. Supp. 2d at 382; see also Takeda Chem. Indus., Ltd., 492
F.3d at 1361.
220 Takeda Chem. Indus., Ltd., 417 F. Supp. 2d at 382.
221 Takeda Chem. Indus., Ltd., 492 F.3d at 1362-63.
210
211

[20:1 2020]

UIC Review of Intellectual Property

23

additional evidence to show what happened in a phenyl compound is expected to be
repeated in a pyridyl compound.
E. Implication II: Motivation Based on Test Data
The Sanofi-Aventis court acknowledged that “taxane modifications were
considered at C2, C4, C5, C7, C8, C9, C10, C11, C12, C13, C14, [C’2], and [C’3]” or
that “taxane researchers investigated substitutions at many positions[.]”222 However,
the Sanofi-Aventis court found no clear error in the district court’s conclusion that “it
would not have been obvious to make simultaneous methoxy substitutions at C7 and
C10 of docetaxel[.]” 223 Thus, the Sanofi-Aventis approach suggests that while
chemical modifications at various positions of a lead compound may have been
routine for an ordinary skilled organic chemist, proving obviousness requires more
evidence to show that a specification modification would have been obvious.
Under the Sanofi-Aventis approach, a reason for simultaneously modifying
specific positions to make a pharmaceutical compound depends on a scientific test for
demonstrating that the anti-disease property may come from such modification. For
instance, the Sanofi-Aventis court noted that “of the references that made individual
methoxy substitutions at C7 or C10, none tested those taxane analogs against drug
resistant cell lines or taught that the analogs would overcome drug resistance.”224
The Sanofi-Aventis approach again followed the Federal Circuit’s case law. In
Takeda Chemical Industries, Ltd., the Federal Circuit opined that the toxicity test
data in Sohda II paper supported the district court’s finding that “homologation had
no tendency to decrease unwanted side effects”225 and, therefore, that researchers
would not have focused on the homologation of compound b.226 A result of testing
even forecloses a desire to modify a lead compound. For example, when analyzing the
issue of homologation, the Takeda court emphasized that “several other compounds
exhibited similar or better potency than compound b, and one compound in particular,
compound 99, that had no identified problems differed significantly from compound b
in structure.”227
In Bristol-Myers Squibb Co., the patent compound was entecavir (Figure 5(a))
used for treating hepatitis B under the trade name Baraclude®.228 The alleged lead
compound was 2’-CDG (Figure 5(b)), a potent antiviral carbocyclic nucleoside analog
Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc., 933 F.3d 1367, 1377-78 (Fed. Cir. 2019).
Id.; see also Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG,
2018 WL 9364037, at *11 (D.N.J. Apr. 25, 2018) (“Defendants, however, failed to demonstrate that a
[person of ordinary skill in the art] would have been motivated to simultaneously modify docetaxel
with a methyl ether at the C-7 and C-10 positions to arrive at cabazitaxel.”).
224 Sanofi-Aventis U.S., LLC, 933 F.3d at 1378.
225 Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1360 (Fed. Cir. 2007)
(quoting Takeda Chem. Indus., Ltd., Inc., 417 F. Supp. 2d at 383).
226 Takeda Chem. Indus., Ltd., 492 F.3d at 1360; see also Takeda Chem. Indus., Ltd., Inc., 417 F.
Supp. 2d at 383 (“One of ordinary skill in the art would therefore have been more likely to conclude
from Sohda II that homologation had no tendency to decrease unwanted side effects and to focus
research efforts elsewhere.”).
227 Sanofi-Aventis U.S., LLC, 933 F.3d at 1360-61.
228 See Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc., 752 F.3d 967, 969 (Fed. Cir. 2014).
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of deoxyguanosine. 229 2’-CDG was structurally different from entecavir, because
entecavir has a carbon-carbon double bond (exocyclic methylene group) at C’5 of the
carbocyclic ring.230
The Bristol-Myers court agreed with the district court’s opinion that in light of
Madhavan 30 compound (Figure 5(c)), it would have been obvious to modify 2’-CDG
to create entecavir.231 Madhavan 30 compound came from a research effort focusing
on nucleoside analogs composed of a carbocyclic ring and adenosine base. 232
Madhavan 30 compound was developed by substituting an exocyclic methylene group
at C’5 position of the carbocyclic ring of aristeromycin.233 Madhavan 30 compound
showed improved antiviral activity over aristeromycin.234 Thus, considering the fact
that a chemist would have sought to make small, conservative changes to C’2 or C’5
of 2’-CDG’s carbocyclic ring, the Bristol-Myers court concluded that an exocyclic
methylene group would have been chosen to modify C’5 position. 235

(a) Entecavir

Id.
Id. at 969-70.
231 Id. at 975-76.
232 Id. at 971.
233 Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc., 923 F. Supp. 2d 602, 628 (D. Del. 2013).
234 Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc., 752 F.3d 967, 975 (Fed. Cir. 2014); see
also Bristol-Myers Squibb Co., 923 F. Supp. 2d at 628.
235 Bristol-Myers Squibb Co., 752 F.3d at 975-76; see also Bristol-Myers Squibb Co., 923 F. Supp.
2d at 667-68 (“These selections equate to a small, finite number of changes to try to the lead
compound, 2’-CDG. Specifically, it would leave six options to pursue: binding a fluorine atom up or
down at the 2 prime or 5 prime position and binding a double-bonded carbon atom30 at the 2 prime
or 5 prime position (although, as previously noted, Glaxo researchers had already made a compound
with a fluorine atom pointing up at the 2 prime position of 2’-CDG).”).
229
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(b) 2’-CDG

(c) Madhavan 30 Compound
Figure 5

V. LEAD COMPOUND ANALYSIS FOR ONGOING DRUG DEVELOPMENT
As explained in Part IV, the Sanofi-Aventis approach requires an obvious path
from the lead compound (paclitaxel or docetaxel) to the patented compound
(cabazitaxel) be based on a scientific expectation. The scientific expectation comes
from both the structural similarity of tested prior art compounds and the test results
of these compounds.236 Part V further demonstrates that the Sanofi-Aventis approach
follows the KSR Court’s principles and is beneficial to ongoing drug development.

236

See supra Part IV.D & E.
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A. Pro-Drug Discovery Approach
Paclitaxel and docetaxel are two cancer drugs developed by two different
research groups in United States and France, respectively.237 Both drugs are based
on the same precursor 10-DAB.238 While paclitaxel was developed by BMS, docetaxel
was developed by PRP that later became Sanofi-Aventis.239 Sanofi-Aventis eventually
created cabazitaxel.240
The development history of paclitaxel, docetaxel and cabazitaxel stands for a
case of the competition of drug discovery between two pharmaceutical companies.241
These drugs belong to the same class of taxanes.242 Researchers from two companies
have published academic articles or filed patent applications for taxane
compounds.243 So, the information given in those public documents may provide a
“good reason to pursue the known options [of functional group modification,]” 244
especially when the research group of cabazitaxel utilized paclitaxel or docetaxel as a
starting point.245 But, the question is what the motivation or reason behind such a
pursuit is.
A pharmaceutical compound is created only to treat a disease or condition, but
“design incentives” may come not only from acquiring therapeutically-related
properties but also from, nowadays, improving physiochemical properties. 246
Particularly, cabazitaxel came from a research intended to treat drug-resistant
tumors.247 The research ended up with simultaneous methoxy substitutions at C7
and C10 positions of docetaxel.248
If the idea of simultaneous methoxy substitutions at C7 and C10 positions was
an improvement, then the question is whether simultaneous methoxy substitutions
at C7 and C10 positions would have been considered as “the predictable use of prior

237 Vivien Walsh & Muriel Le Roux, Contingency in Innovation and the Role of National
Systems: Taxol and Taxotère in the USA and France, 33 RESEARCH POLICY 1307, 1307-08 (2004).
238 See supra Part I.
239 See Yeda Research and Dev. Co. v. Imclone Sys. Inc., 443 F. Supp. 2d 570, 578 (S.D.N.Y.
2006) (“In 1990, the Rorer Group merged with the health care arm of Rhone-Poulenc, forming
Rhone-Poulenc Rorer, Inc. (‘RPR’). Nine years later, RPR merged with Hoechst-Marion-Roussel to
form Aventis. In 2004, Aventis was acquired by Sanofi-Synthelabo, forming the sanofi-aventis Group.
Defendant Aventis Pharmaceuticals is a wholly-owned subsidiary of the sanofi-aventis Group.”).
240 See supra Part IV.A.
241 See supra Part I.
242 See supra Part I.
243 See supra Part IV.B.
244 KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 421 (2007).
245 See Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. CV147869MASLHG, 2018
WL 9364037, at *4 (D.N.J. Apr. 25, 2018) (“Around 1989, Sanofi launched a medicinal chemistry
program to search for taxane analogs to treat cancers. The program used existing taxanes, docetaxel,
which was then under development by Sanofi, and paclitaxel, as reference compounds.” (internal
citations omitted)).
246 Margaret S. Landis et al., Commentary: Why Pharmaceutical Scientists in Early Drug
Discovery Are Critical for Influencing the Design and Selection of Optimal Drug Candidates, 19(1)
AAPS PHARMSCITECH 1, 1-3 (2018).
247 See supra Part I.
248 See supra Part IV.A.
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art elements according to their established functions.” 249 As the KSR Court has
required, three factors must be evaluated together: (1) “interrelated teachings of
multiple patents”; (2) “the effects of demands known to the design community or
present in the marketplace”; and (3) “the background knowledge possessed by a
person having ordinary skill in the art.”250 Unfortunately, the defendant in SanofiAventis U.S., LLC failed to present any scientific evidence, such as test data in those
prior art references or non-conclusory, specified expert testimony, to show the
teaching or knowledge of the effect of simultaneous C7 and C10 methoxy
substitutions on drug-resistant tumor cells.251
The KSR Court also required that the obviousness analysis “should be made
explicit.”252 However, the explicit analysis can rely on “the inferences and creative
steps that a person of ordinary skill in the art would employ.”253 Unfortunately, in
Sanofi-Aventis U.S., LLC, the prior art references disclosing taxane analogs with an
individual methoxy substitution at C7 or C10 position did not provide any test data
on drug-resistant cell lines or teach that those taxane analogs would overcome drug
resistance. 254 Therefore, no inference or creative step could be drawn from these
references.
In conclusion, the Sanofi-Aventis approach follows the KSR Court’s principles
and establishes an evidentiary standard for determining the nonobviousness
requirement of pharmaceutical compound patents. With that, a pharmaceutical
compound evolving from its ancestor compounds can be patentable under 35 U.S.C. §
103, if the effect of an alleged modification was unknown back then.
B. Hindsight-Free Approach
As Taryn Elliott contended, “[p]ost-KSR courts maintain that the Non-Rigid
TSM rationale remains the primary guarantor against a nonstatutory hindsight bias
because the Non-Rigid TSM rationale ensures that the obviousness determination is
based on evidence.”255 Focusing on the test result of a prior art compound has guided
the determination of whether an alleged modification would have been obvious.256
The Sanofi-Aventis approach can further avoid a hindsight-based analysis of
obviousness.
While recognizing that Golik’s patent disclosed “a taxane analog with a
methylthiomethoxy [(H3C-S-H2CO-)] substitution at C7, which had promising
qualities against drug-resistant cell lines[,]” the Sanofi-Aventis court rejected the
defendant’s attempt to extend the disclosure to the teaching of making a methoxy

KSR Int’l Co., 550 U.S. at 417.
Id. at 418.
251 Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc., 933 F.3d 1367, 1378-80 (Fed. Cir. 2019).
252 KSR Int’l Co., 550 U.S. at 418.
253 Id.
254 Sanofi-Aventis U.S., LLC, 933 F.3d at 1378.
255 Taryn Elliott, Post-KSR Obviousness: The Effects of the Patent and Trademark Office’s
Exemplary Rationales on Patent Litigation, 16 GEO. MASON L. REV. 1011, 1088-89 (2009).
256 See supra Part IV.E.
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(H3CO-) substation at C7.257 The defendant’s argument seemed to rely on structural
similarity between methylthiomethoxy and methoxy, but the Sanofi-Aventis court
criticized the argument as “little more than hindsight.”258 As a result, the SanofiAventis court not only affirmed the district court’s finding “no evidence that the
methoxy group would provide a similar benefit as the sulfur-containing
methylthiomethoxy group[,]” but also pointed out “the absence of any evidence
showing equivalent properties of a methoxy substitution[.]”259
The Sanofi-Aventis court also denied the defendant’s another attempt to rely on
Ojima’s article allegedly teaching the benefits of an acetoxy group at C10 against
drug-resistant cells. 260 The defendant argued that Ojima’s article would have
motivated a methoxy substitution at C10. 261 But, the Sanofi-Aventis court again
found “no non-conclusory evidence that the methoxy group would have the same
purported benefits as the acetoxy group[.]”262
However, the Sanofi-Aventis approach is not a rigid test, because the SanofiAventis court only required, for example, “persuasive explanation of how the methoxy
group, which was not tested in [Ojima’s article], would be a more conservative choice
than the C10 acetoxy already present in the FDA-approved drug paclitaxel.”263 That
is, the Sanofi-Aventis approach accepts the source of motivation from something
other than Ojima’s article. In fact, the Sanofi-Aventis approach complies with the
KSR Court’s opinion that “[a] factfinder should be aware, of course, of the distortion
caused by hindsight bias and must be cautious of arguments reliant upon ex post
reasoning.”264
C. Flexible TSM Test
The KSR Court rejected the Federal Circuit’s rigid approach to the TSM test and
reasoned that “[its] cases have set forth an expansive and flexible approach[.]”265
However, the Supreme Court did not fully abrogate the TSM test. 266 Some
commentators have noted that the Federal Circuit in the post-KSR era has adopted a
modified TSM test.267 For instance, Emer Simic stated that the Federal Circuit still
Sanofi-Aventis U.S., LLC, 933 F.3d at 1379.
Id.
259 Id.
260 See id.
261 See id.
262 Sanofi-Aventis U.S., LLC, 933 F.3d at 1379.
263 Id. at 1379-80.
264 KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 421 (2007).
265 Id. at 415.
266 Thomas G. Hungar & Rajiv Mohan, A Case Study Regarding the Ongoing Dialogue Between
the Federal Circuit and the Supreme Court: The Federal Circuit’s Implementation of KSR v. Teleflex,
66 SMU L. REV. 559, 562 (2013).
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requires “an explicit reason for why a certain option was ‘obvious to try’ before the
court will determine an invention to be obvious.”268
In fact, the KSR Court allowed the Federal Circuit to develop a flexible version
of the TSM test. 269 But, for pharmaceutical compound patents, Prof. Douglas L.
Rogers concluded that “[a]lthough some of these cases refer to applying the test
‘flexibly,’ they are really referring to applying the TSM test flexibly to determine if
prior art showed the lead compound and each subsequent step up to the final
compound[.]”270 The Sanofi-Aventis approach may reinstate Prof. Rogers’ conclusion.
The Sanofi-Aventis court defined what a flexible standard means by
distinguishing itself from the Bristol-Myers decision. 271 First, the Sanofi-Aventis
court considered the Bristol-Myers decision as affirming “a district court’s conclusion
that it would have been obvious to make a single chemical change to a lead compound
where there were a ‘small, finite number of changes to try,’ and the particular
claimed change had already been shown to have desirable properties in a similar
context.” 272 Second, the Sanofi-Aventis court emphasized that “the district court’s
findings in this case are quite different” from Bristol-Myers Squibb Co.273 The SanofiAventis court noted that “numerous docetaxel modifications were under investigation,
and there was no showing that making individual or simultaneous methoxy
substitutions at C7 and C10 improved activity against drug-resistant cells, the sole
motivation relied on by [the defendant].” 274 Therefore, the Sanofi-Aventis court
opined that the present case “demand[s] a different outcome.”275
The Bristol-Myers decision actually follows the KSR Court’s notion that “[w]hen
there is a design need or market pressure to solve a problem and there are a finite
number of identified, predictable solutions, a person of ordinary skill has good reason
to pursue the known options within his or her technical grasp.” 276 However, the
Sanofi-Aventis court characterized Bristol-Myers Squibb Co. as providing “a brightline legal rule [which] would be inconsistent with the flexible analysis inherent to the
highly contextual obviousness inquiry.” 277 Consequently, the Sanofi-Aventis court
rejected a view that “small changes to a compound are necessarily prima facie
obvious.”278
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Nonetheless, the Sanofi-Aventis approach does not contrast with the KSR
Court’s notion, because the situation of numerous modification options (e.g., C2, C4,
C5, C7, C8, C9, C10, C11, C12, C13, C14, C’2, and C’3), 279 rather than “a finite
number of identified, predictable solutions,” in the present case would not have led a
person of ordinary skill to reasonably pursue individual or simultaneous methoxy
substitutions at C7 and C10. Therefore, it is fair to say that the Sanofi-Aventis
approach is a flexible TSM test.
VI. CONCLUSION
Whether a pharmaceutical compound acquires patentability under 35 U.S.C. §
103 depends on whether one of ordinary skill in the art would have “a reason or
motivation to modify a lead compound to make the claimed compound with a
reasonable expectation of success.” 280 Courts may also adjudicate whether one of
ordinary skill in the art would have selected the alleged compound as a lead
compound.281 Alternatively, courts may ask only whether one of ordinary skill in the
art would have modified “a known compound in a particular manner to establish
prima facie obviousness of a new claimed compound.”282
The Sanofi-Aventis decision advances the nonobviousness standard for
pharmaceutical compound patents by requiring showing a scientific expectation.
That is, a defendant must base its obviousness reasoning on both the structural
similarity of prior art compounds tested and the test results of these compounds.
Under the Sanofi-Aventis approach, a pharmaceutical compound is more likely
patentable under 35 U.S.C. § 103, even though it is derived from its ancestor
compounds. These ancestor compounds may have been published or patented, so that
various functional groups on them become prior art structures. However, as long as
these functional groups are not shown by test data to connect to any improved
property of the claimed compound, obviousness cannot be sustained.
Lastly, although the Sanofi-Aventis approach requires an evidence-based
obviousness analysis, it is not a rigid test opposed by the KSR Court. The SanofiAventis approach still accepts non-conclusory expert opinions. On the other hand, a
hindsight-based obviousness analysis can be avoided when modification options
based on structural similarity are lack of a sound explanation.
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